Current Report Filing (8-k)
2023年1月28日 - 6:06AM
Edgar (US Regulatory)
0001859007
false
0001859007
2023-01-27
2023-01-27
0001859007
dei:FormerAddressMember
2023-01-27
2023-01-27
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): January 27, 2023
ZYVERSA
THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-41184 |
|
86-2685744 |
(State or other jurisdiction |
|
(Commission |
|
(I.R.S. Employer |
of incorporation) |
|
File Number) |
|
Identification No.) |
2200
N. Commerce Parkway, Suite 208
Weston,
Florida |
|
33326 |
(Address of principal executive
offices) |
|
(Zip Code) |
(754)
231-1688
(Registrant’s
telephone number, including area code)
Larkspur
Health Acquisition Corp.
100
Somerset Corporate Blvd., 2nd Floor
Bridgewater,
New Jersey 08807
(Former
name or former address if changed from last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of Each Class |
|
Trading
Symbols |
|
Name
of each exchange on which registered |
Common Stock, par value
$0.0001 per share |
|
ZVSA |
|
The Nasdaq Global Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
8.01. Other Events.
On
January 27, 2023,
the Company issued a press release reporting the inducement grant under Nasdaq Listing Rule 5635(c)(4) to its newly appointed Chief Medical
Officer, a copy of which is furnished as Exhibit 99.1 hereto.
(c)
Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
January 27, 2023 |
|
|
|
By: |
/s/ Stephen
Glover |
|
Name: |
Stephen C. Glover |
|
Title: |
Chief Executive Officer |
Larkspur Health Acquisit... (NASDAQ:LSPRU)
過去 株価チャート
から 8 2024 まで 9 2024
Larkspur Health Acquisit... (NASDAQ:LSPRU)
過去 株価チャート
から 9 2023 まで 9 2024